STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Avidity and Affiliates Report Shared Voting Power over 9.9% of CNTX

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Avidity Partners and affiliated funds filed a Schedule 13G reporting significant passive holdings in Context Therapeutics Inc. The filing discloses that certain Avidity reporting persons hold shared voting and shared dispositive power over 9,126,176 shares, representing approximately 9.9% of the outstanding common stock. Individual fund positions reported in the filing include Avidity Master Fund LP with 5,183,700 shares (5.6%) and Avidity Private Master Fund I LP with 7,776,296 shares (8.4%). Michael Gregory is listed among the reporting persons with the same shared power totaling 9,126,176 shares.

The filing indicates no sole voting or dispositive power for any reporting person and includes a certification that the securities were not acquired to change or influence control of the issuer. Exhibits referenced in the filing include a Joint Filing Agreement and Control Person Identification.

Positive

  • Reported beneficial ownership of 9,126,176 shares representing 9.9% of Context Therapeutics common stock.
  • Detailed fund-level positions disclosed, including 5,183,700 shares (5.6%) for Avidity Master Fund LP and 7,776,296 shares (8.4%) for Avidity Private Master Fund I LP.
  • Filed Schedule 13G with a certification of passive intent and included exhibits (Joint Filing Agreement and Control Person Identification) as part of the disclosure.

Negative

  • None.

Insights

TL;DR: Avidity reports a material passive stake of 9.9% in CNTX with shared voting/dispositive power; this is a notable ownership disclosure for investors.

The Schedule 13G shows Avidity-affiliated entities collectively holding 9,126,176 shares (9.9%) of Context Therapeutics common stock and reporting only shared voting and dispositive powers. The filing is a passive disclosure rather than an active 13D claim, and it includes a formal certification that the holdings were not acquired to influence control. For investors, the key facts are the size of the position and the coordinated reporting across multiple Avidity entities, both explicitly stated in the filing.

TL;DR: Coordinated Avidity ownership is disclosed as passive (Schedule 13G) with shared powers; governance impact is limited absent additional actions.

The filing documents shared voting and dispositive power across several Avidity entities rather than any sole control. Reported fund-level holdings include 5,183,700 shares (5.6%) for Avidity Master Fund LP and 7,776,296 shares (8.4%) for Avidity Private Master Fund I LP, with aggregate shared power of 9,126,176 shares (9.9%). The report includes a certification stating the securities were not acquired to change or influence control and attaches a Joint Filing Agreement and Control Person Identification exhibit, all as stated in the document.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Avidity Partners Management LP
Signature:By: Avidity Partners Management (GP) LLC, its general partner, By: /s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Partners Management (GP) LLC
Signature:/s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Capital Partners Fund (GP) LP
Signature:By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Capital Partners (GP) LLC
Signature:/s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Master Fund LP
Signature:By: Avidity Capital Partners Fund (GP) LP, its general partner, By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Private Master Fund I LP
Signature:By: Avidity Capital Partners Fund (GP) LP, its general partner, By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Michael Gregory
Signature:/s/ Michael Gregory
Name/Title:Michael Gregory
Date:08/14/2025

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Exhibit Information

[Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

FAQ

How many shares of CNTX does Avidity beneficially own?

The filing reports aggregated shared beneficial ownership of 9,126,176 shares of Context Therapeutics (CNTX).

What percentage of CNTX common stock does Avidity report owning?

Avidity and affiliated reporting persons disclose ownership equal to approximately 9.9% of CNTX common stock.

Do any reporting persons have sole voting or dispositive power over the shares?

No; the filing states 0 sole voting power and 0 sole dispositive power for each reporting person, with only shared powers reported.

Which Avidity funds are specifically identified and what are their reported holdings?

The filing lists Avidity Master Fund LP with 5,183,700 shares (5.6%) and Avidity Private Master Fund I LP with 7,776,296 shares (8.4%), among other Avidity entities reporting shared power.

Does the filing state intent to influence control of Context Therapeutics (CNTX)?

The filing includes a certification stating the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Context Therapeutics Inc

NASDAQ:CNTX

CNTX Rankings

CNTX Latest News

CNTX Latest SEC Filings

CNTX Stock Data

95.55M
90.73M
2.33%
76.79%
0.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
PHILADELPHIA